Besch Doug's Insider Trades & SAST Disclosures
Besch Doug's most recent trade in OptimizeRx Corp was a trade of 1,386 Common Stock done at an average price of $6.6 . Disclosure was reported to the exchange on Feb. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Besch Doug.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 15 Feb 2025 | 1,386 | 51,605 (0%) | 0% | 6.6 | 9,203 | Common Stock |
| OptimizeRx Corp | Besch Doug | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 77,742 | 77,742 | - | - | Stock Option | |
| OptimizeRx Corp | Besch Doug | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 41,408 | 52,991 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 1,964 | 3,928 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Besch Doug | Chief Product Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 1,964 | 12,160 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Besch Doug | Chief Product Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.75 per share. | 19 Dec 2024 | 577 | 11,583 (0%) | 0% | 4.8 | 2,741 | Common Stock |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 3,324 | 3,325 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 3,324 | 11,172 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.83 per share. | 03 Oct 2024 | 976 | 10,196 (0%) | 0% | 7.8 | 7,642 | Common Stock |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 7,848 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2023 | 5,892 | 5,892 | - | - | Stock Option | |
| OptimizeRx Corp | Besch Doug | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2023 | 5,892 | 5,892 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2023 | 3,324 | 6,649 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2023 | 3,324 | 4,824 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.06 per share. | 03 Oct 2023 | 976 | 3,848 (0%) | 0% | 7.1 | 6,891 | Common Stock |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 19,527 | 19,527 | - | - | Stock Option | |
| OptimizeRx Corp | Doug Besch | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 9,973 | 9,973 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges